An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models
Viruses · 2026
DOI: 10.3390/v18090976 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Zikang Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102,…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, COVID-19, SARS-CoV-2. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The continued evolution of SARS-CoV-2 has reduced the protective effectiveness of first-generation vaccines and underscores the need for broadly reactive next-generation vaccine candidates. Here, we evaluated STFKB, an alum-adjuvanted bivalent recombinant protein vaccine composed of the monomeric Spike (STFKprototype) and the engineered Spike (STFK1628X). We assessed the immunogenicity, tolerability, and protective efficacy of STFKB in mice, rats, guinea pigs, rhesus macaques, and Syrian hamsters. STFKB induced robust STFK- and STFK1628X-specific antibody responses and broadly reactive neutralizing antibodies against multiple SARS-CoV-2 variants in the tested animal models. In hamster challenge studies, STFKB vaccination protected animals from Omicron BA.1 and BA.5 challenge, as shown by reduced body-weight loss, lower viral RNA loads in respiratory tissues, and improved gross lung pathology. Across the tested preclinical models, STFKB was well tolerated, with no vaccine-related overt toxicity observed under the study conditions. These findings support the rationale and translational potential of the bivalent vaccine strategy proposed in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.
- National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361102, China.
ORCID-Profile: Ningshao Xia
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Z., Gao, J., Bai, R., Yuan, L., Guo, H., Wang, S., Wang, Y., Wu, J., Bu, Q., Guo, H., Hong, Y., Ma, J., Wang, K., Guo, W., Liu, Y., Weng, Z., Zhang, T., Xia, N., Yuan, Q., …, & Wu, Y. (2026). An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models. Viruses. https://doi.org/10.3390/v18090976
Vancouver
Wang Z, Gao J, Bai R, Yuan L, Guo H, Wang S, et al. An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models. Viruses. 2026. doi:10.3390/v18090976
BibTeX
@article{Wang2026,
author = {Wang, Zikang and Gao, Jiahua and Bai, Ruojing and Yuan, Lunzhi and Guo, Huilin and Wang, Shaojuan and Wang, Youfeng and Wu, Jiayi and Bu, Qingfang and Guo, Huiyu and Hong, Yunda and Ma, Jian and Wang, Kai and Guo, Wenjie and Liu, Yanyan and Weng, Zhitao and Zhang, Tianying and Xia, Ningshao and Yuan, Quan and Zhang, Yali and Wu, Yangtao},
title = {An Engineered Spike Immunogen Drives Broad Protection of a Bivalent Recombinant Protein COVID-19 Vaccine in Animal Models},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18090976}
}
EUVIMED